Q32 Bio Past Earnings Performance
Past criteria checks 0/6
Q32 Bio's earnings have been declining at an average annual rate of -48%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 227.3% per year.
Key information
-48.0%
Earnings growth rate
-2.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -227.3% |
| Return on equity | -170.2% |
| Net Margin | 445.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Q32 Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | -13 | -57 | 15 | 0 |
| 31 Mar 24 | -10 | -46 | 12 | 0 |
| 31 Dec 23 | -7 | -54 | 10 | 0 |
| 30 Sep 23 | 12 | -36 | 10 | 0 |
| 31 Dec 22 | 7 | -43 | 10 | 0 |
Quality Earnings: DB0 is currently unprofitable.
Growing Profit Margin: DB0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DB0's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare DB0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DB0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: DB0 has a negative Return on Equity (-170.23%), as it is currently unprofitable.